Gilead Sciences, Inc. (GILD) Holdings Lowered by Psagot Investment House Ltd.

Psagot Investment House Ltd. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 37.1% during the third quarter, Holdings Channel reports. The firm owned 200,651 shares of the biopharmaceutical company’s stock after selling 118,447 shares during the quarter. Psagot Investment House Ltd.’s holdings in Gilead Sciences were worth $15,492,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GILD. Reilly Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 98.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $132,000. Brand Asset Management Group Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $139,000. TRUE Private Wealth Advisors acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $174,000. Finally, Wealthsource Partners LLC acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $206,000. 78.09% of the stock is currently owned by institutional investors.

Several research analysts have recently issued reports on GILD shares. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday, October 11th. Mizuho restated a “buy” rating and issued a $94.00 target price on shares of Gilead Sciences in a report on Friday, August 10th. Piper Jaffray Companies set a $85.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, September 12th. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research note on Wednesday, July 18th. Twelve investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $87.84.

Shares of Gilead Sciences stock opened at $71.18 on Friday. The firm has a market cap of $93.76 billion, a price-to-earnings ratio of 11.29, a PEG ratio of -2.81 and a beta of 1.01. The company has a quick ratio of 3.39, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a one year low of $64.27 and a one year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the Zacks’ consensus estimate of $1.63 by $0.21. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same quarter in the prior year, the firm earned $2.27 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. Gilead Sciences’s payout ratio is currently 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $239,408,146.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 150,000 shares of company stock valued at $11,087,500. 1.30% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding GILD? Visit to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.

Leave a Reply